<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev cubana med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232021000300010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación de la fibrogénesis hepática en pacientes con esteatohepatitis no alcohólica tratados con propóleos rojo oral cubano]]></article-title>
<article-title xml:lang="en"><![CDATA[Evaluation of hepatic fibrogenesis in patients with nonalcoholic steatohepatitis treated with cuban oral red propolis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velbes Marquetti]]></surname>
<given-names><![CDATA[Pedro E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Barrios]]></surname>
<given-names><![CDATA[Suseily]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto Matos]]></surname>
<given-names><![CDATA[Josánne]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Castro]]></surname>
<given-names><![CDATA[Jorge L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Piñero]]></surname>
<given-names><![CDATA[Adolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínico Quirúrgico &#8220;Hermanos Ameijeiras&#8221;  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>60</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232021000300010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232021000300010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232021000300010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La enfermedad por depósito graso no alcohólica constituye una pandemia del mundo contemporáneo. Su espectro silente atraviesa estadios de cronicidad y puede llegar a la cirrosis hepática y sobre esta pudiera desarrollarse un hepatocarcinoma. No existen tratamientos y solo se puede actuar sobre los factores de riesgo.  Objetivo:  Evaluar el efecto citohepatoprotector y antifibrótico del propóleos rojo cubano oral en pacientes con esteatohepatitis no alcohólica.  Métodos:  Se realizó un estudio longitudinal prospectivo en pacientes seleccionados de las consultas de Gastroenterología, Endocrinología y Medicina Interna del Hospital Clínico Quirúrgico&#8221; Hermanos Ameijeiras&#8221; durante el periodo de abril 2017 a abril 2018. El universo de estudio fue de 120 pacientes con diagnóstico imagenológico de hígado graso. La muestra quedó conformada por 70 pacientes con diagnóstico de hígado graso, y que cumplieron criterios de inclusión y exclusión. Las pruebas estadísticas aplicadas fueron análisis de frecuencia y porcentaje para las variables demográficas. La prueba T para las muestras relacionadas evaluó el comportamiento enzimático al inicio y al final del tratamiento y los cambios elastográficos fueron analizados mediante test de Kappa y porcentaje.  Resultados: Las variables bioquímicas estudiadas mostraron una disminución estadísticamente significativa al final del tratamiento. Los cambios elastográficos al final del estudio evidenciaron la efectividad del tratamiento, en el cual el 91,4 % de los pacientes evolucionaron hacia el menor grado de fibrosis.  Conclusiones:  El propóleos rojo cubano demostró ser un apifármaco con acción citohepatoprotectora y antifibrótica de valor terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Nonalcoholic fat deposition disease is a pandemic in the contemporary world. Its silent spectrum goes through stages of chronicity and it can reach liver cirrhosis and on this a hepatic carcinoma could develop. There are no treatments and medical handling can act on only risk factors.  Objective:  To evaluate cytohepatoprotective and antifibrotic effect of oral Cuban red propolis in patients with nonalcoholic steatohepatitis.  Methods:  A prospective longitudinal study was carried out in selected patients from the Gastroenterology, Endocrinology and Internal Medicine consultations at Hermanos Ameijeiras Clinical Surgical Hospital from April 2017 to April 2018. The study universe was 120 patients with imaging diagnosis of fatty liver. The sample consisted of 70 patients with fatty liver diagnosis, who met the inclusion and exclusion criteria. Frequency and percentage analysis for the demographic variables were the statistical tests applied. The T test for the related samples evaluated the enzymatic behavior at the beginning and at the end of the treatment and the elastography changes were analyzed using Kappa and percentage tests.  Results:  The biochemical variables studied showed statistically significant decrease at the end of the treatment, which evidenced the effectiveness of the treatment. 91.4% of the patients progressed to a lower degree of fibrosis.  Conclusions:  Cuban red propolis proved to be a therapeutic drug with cytohepathoprotective and antifibrotic action.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[esteatohepatitis no alcohólica]]></kwd>
<kwd lng="es"><![CDATA[propóleos]]></kwd>
<kwd lng="es"><![CDATA[propóleos rojo cubano]]></kwd>
<kwd lng="es"><![CDATA[nash score]]></kwd>
<kwd lng="es"><![CDATA[elastografía hepática o fibroscan]]></kwd>
<kwd lng="en"><![CDATA[nonalcoholic steatohepatitis]]></kwd>
<kwd lng="en"><![CDATA[propolis]]></kwd>
<kwd lng="en"><![CDATA[Cuban red propolis]]></kwd>
<kwd lng="en"><![CDATA[nash score]]></kwd>
<kwd lng="en"><![CDATA[liver elastography or fibroscan]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Casas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Etiopatogenia, diagnóstico y tratamiento de la enfermedad del hígado graso no alcohólico]]></article-title>
<source><![CDATA[Rev. Esp. Enferm. Diag]]></source>
<year>2013</year>
<volume>105</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>409-20</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdelho Machado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés Pinto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-alcoholic fatty liver disease: What the clinician needs to know]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2014</year>
<volume>20</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>12956-80</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz Morales]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso Rodríguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Velbes Marquetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Cast]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobre las asociaciones entre el hígado graso no alcohólico y la insulino resistencia]]></article-title>
<source><![CDATA[Revista Cubana de Alimentación y Nutrición]]></source>
<year>2017</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1561-2929</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chao Pereira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesidad y mortalidad en los pacientes con insuficiencia cardiaca crónica]]></article-title>
<source><![CDATA[Revista Cubana de Medicina]]></source>
<year>2018</year>
<volume>57</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>International Diabetes Federation: IDF</collab>
<source><![CDATA[Diabetes Atlas: Key Messages]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Golabi]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Paik]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States]]></article-title>
<source><![CDATA[BMC Gastroenterol]]></source>
<year>2019</year>
<volume>19</volume>
<page-range>56</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kagana Valdés]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cuesta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cuellar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferras]]></surname>
<given-names><![CDATA[BI]]></given-names>
</name>
</person-group>
<source><![CDATA[Actividad inhibitoria del propóleos rojo cubano de Nueva Paz y Melena del Sur]]></source>
<year></year>
<conf-name><![CDATA[ IV Simposio de Propóleos y 111 de Apiterapia]]></conf-name>
<conf-date>1996</conf-date>
<conf-loc>La Habana, Cuba </conf-loc>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Rochet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Balbuena]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Esteatosis hepática en diabéticos comportamiento en el Hospital saturnino Lora durante un año]]></source>
<year>2005</year>
<publisher-name><![CDATA[Instituto Superior de Ciencias Médicas Santiago de Cuba]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Acosta]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Velbes Marquetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez Álvarez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores pronósticos de la fibrosis hepática en pacientes diabéticos, tipo 2 con hígado graso no alcohólico]]></source>
<year>2009</year>
<publisher-loc><![CDATA[C. Habana ]]></publisher-loc>
<publisher-name><![CDATA[Hermanos Ameijeiras]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osman]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Osman]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abnormal glucose tolerance and non-esterified fatty acids (NEF As) as predictors of non-alcoholic steatohepatitis (NASH): which Ash that ignites the NASH]]></article-title>
<source><![CDATA[J Clin. Gastroenterol]]></source>
<year>2007</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>118-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kersenovich]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[]]></source>
<year></year>
<conf-name><![CDATA[ Fibrogénesis hepática. Stress oxidativo (comunicación personal/2015)]]></conf-name>
<conf-date>2015</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández Vega]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Velbes Marquetti]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Nassip Hadah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez Alvarez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Soto Matos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Giralt Rivero]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efecto del tratamiento con extracto de propóleos rojo oral en la Esteatohepatitis no alcohólica]]></article-title>
<source><![CDATA[Rev. Cub. de Medicina]]></source>
<year>2014</year>
<volume>53</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>282-90</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pietrangelo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metals Oxidative stress and hepatic fibrogénesis]]></article-title>
<source><![CDATA[Semin Liver Dis]]></source>
<year>1998</year>
<volume>16</volume>
<page-range>13-30</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rafeeg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kenneth]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)]]></article-title>
<source><![CDATA[Annals of Medicine]]></source>
<year>2009</year>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Monitoring occurrence of liver-related events and survival by transient elastography in patient with nonalcoholic fatty liver disease and compensated and advanced chronic liver disease]]></source>
<year>2020</year>
<publisher-name><![CDATA[Clin Gastroenterol Hepatol]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merriman]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrell]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Patti]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Weston]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlation of paired liver biopsies in morbidly obese patients with suspected no-alcoholic fatty liver disease]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2006</year>
<volume>44</volume>
<page-range>874-80</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velbes Marquetti]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<source><![CDATA[Propóleos Rojo Oral Cubano en la Esteatohepatitis no alcohólica]]></source>
<year>2020</year>
<publisher-loc><![CDATA[La Habana. Cuba ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Nuevo Milenio]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
